Pancreas
Journal Abbreviation: PANCREAS
ISSN: 0885-3177
eISSN: 1536-4828
Publisher: Lippincott, Williams & Wilkins
Publications (18)
Relationship Between Metabolic Toxicity and Efficacy of Everolimus in Patients With Neuroendocrine Tumors (NETs): A Pooled Analysis From the Randomized, Phase 3 RADIANT-3, and RADIANT-4 Trials (2019)
Fazio N, Carnaghi C, Valle JW, Herbst F, Ridolfi A, Strosberg J, Kulke MH, et al.
Conference contribution
Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes With Everolimus: A Pooled Analysis From the Randomized, Phase 3 RADIANT-3, and RADIANT-4 Trials (2019)
Chan DL, Yao JC, Camaghi C, Herbst F, Ridolfi A, Strosberg J, Kulke MH, et al.
Conference contribution
Final Progression-Free Survival Analyses for Lanreotide Autogel/Depot 120 mg in Metastatic Enteropancreatic Neuroendocrine Tumors: The CLARINET Extension Study (2018)
Wolin EM, Pavel ME, Cwikla JB, Phan AT, Raderer M, Sedlackova E, Cadiot G, et al.
Conference contribution
Efficacy and Safety of Telotristat Ethyl in Patients With Carcinoid Syndrome Inadequately Controlled by Somatostatin Analogs: Analysis of the Completed TELESTAR Extension Period (2018)
Hoersch D, Kulke MH, Caplin ME, Anthony LB, Bergsland E, Oberg K, Warner RRP, et al.
Conference contribution
Integrated Safety Analysis of Telotristat Ethyl in Patients With Carcinoid Heart Disease (2018)
Lapuerta P, Kulke MH, Pavel ME, Biran T, Fleming R, Zacks JS, Hoffmanns P, Warner RRP
Conference contribution
Weight Change Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome (2018)
Weickert MO, Kaltsas G, Hoersch D, Lapuerta P, Pavel ME, Valle JW, Caplin ME, et al.
Journal article
Time to Sustained Improvement in Bowel Movement Frequency With Telotristat Ethyl: Analysis of the Phase 3 TELESTAR Study (2018)
Dillon JS, Kulke MH, Pavel ME, Horsch D, Anthony LB, Warner RRP, Bergsland E, et al.
Conference contribution
Telotristat Ethyl in Carcinoid Syndrome: Safety and Efficacy Results of an Open-Label Extension of the TELECAST Phase 3 Clinical Trial (2018)
Pavel M, Benavent M, Perros P, Srirajaskanthan R, Warner RRP, Kulke MH, Anthony LB, et al.
Conference contribution